Q-omics provides the consensus-scored TMEM44-AS1 profile across patient tissues and cancer cell-line models. TMEM44-AS1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM44-AS1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, TMEM44-AS1 RNA expression shows 18,207 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, THCA, and LSCC as cancer lineages where TMEM44-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM44-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM44-AS1 survival associations across molecular data types. TMEM44-AS1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM44-AS1 RNA expression–survival associations across cancer types. High TMEM44-AS1 expression shows unfavorable associations in ACC, LIHC and STAD, but favorable associations in UVM, LUSC and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM44-AS1 RNA expression.
This table summarizes TMEM44-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM44-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM44-AS1 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, HNSC, LUSC and BLCA. The THCA box plot shows higher TMEM44-AS1 RNA expression in normal versus tumor tissue (log2 FC = −1.509, t-test p < 0.001).
This table shows molecular features associated with TMEM44-AS1 in patient tissues and cancer cell lines. In patient samples, TMEM44-AS1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
